About 4:59
4:59 (also known as 4:59 NewCo) is the hands-on internal incubation initiative of 5AM Ventures, a life science venture capital firm. It discovers, incubates, and funds breakthrough science by partnering alongside academics and entrepreneurs—often as an extension of the operating team—to establish proof-of-concept data that enables a Series A financing. The initiative operates within the biotechnology research space and has spun out multiple companies, including Precede Biosciences and Expansion Therapeutics.
Company details
Founders
Andrew (Andy) J. Schwab
Co-founder of 5AM Ventures in 2002; Managing Partner leading the firm's investments across life sciences and biotech.
LinkedInJohn D. Diekman, PhD
Princeton- and Stanford-trained chemist; co-founded 5AM Ventures in 2002 after serving as CEO of Affymetrix and MD of Affymax; also founded Bay City Capital.
Kush Parmar, MD, PhD
Managing Partner at 5AM Ventures; former NIH-sponsored MD/PhD Physician Scientist Fellow at Harvard Medical School; serves on boards of multiple biotech companies.
LinkedInDeborah Palestrant
PhD in biochemistry and molecular biophysics from Columbia University, MBA from Northeastern University. Previously VP of Corporate Development & Strategy at Relay Therapeutics, led business development at Editas Medicine from inception, and was a lab head at the Novartis Institutes for Biomedical Research. Joined 5AM Ventures as Partner and Head of 4:59 in 2018.
LinkedInAndy J. Schwab
Co-founded 5AM Ventures in 2002 alongside John Diekman. Serves as Managing Partner overseeing the firm's life science investment activities.
What happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.